Different disease progression patterns based on RECIST and CA-125 criteria and the impact on prognosis in patients with ovarian cancer treated with PARP inhibitors.

被引：0
|
作者：
Song, Kun [1 ]
Ma, Yana [1 ]
Bu, Hualei [1 ]
Zhang, Yawen [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17536
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors
    Ma, Yana
    Lv, Weiwei
    Bu, Hualei
    Kong, Beihua
    Song, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Retrospective analysis of ovarian cancer patients treated with PARP inhibitors.
    Liang, Connie
    Leung, Ashley
    Lee, Chung-Shien
    Hernandez, Jennifer
    Cheng, Kit
    Stefanov, Dimitre C.
    John, Veena S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] RECIST is more sensitive than CA-125 in detecting disease progression in epithelial ovarian cancer patients treated with maintenance bevacizumab: A secondary analysis of the ROSIA trial
    Lavie, O.
    Feferkorn, I.
    Frenkel, O.
    Segev, Y.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 117 - 117
  • [4] Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
    Zebic, Danka Sinikovic
    Tjokrowidjaja, Angelina
    Francis, Katherine Elizabeth
    Friedlander, Michael
    Gebski, Val
    Lortholary, Alain
    Joly, Florence
    Hasenburg, Annette
    Mirza, Mansoor
    Denison, Ursula
    Cecere, Sabrina Chiara
    Ferrero, Annamaria
    Pujade-Lauraine, Eric
    Lee, Chee Khoon
    BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 425 - 433
  • [5] Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
    Danka Sinikovic Zebic
    Angelina Tjokrowidjaja
    Katherine Elizabeth Francis
    Michael Friedlander
    Val Gebski
    Alain Lortholary
    Florence Joly
    Annette Hasenburg
    Mansoor Mirza
    Ursula Denison
    Sabrina Chiara Cecere
    Annamaria Ferrero
    Eric Pujade-Lauraine
    Chee Khoon Lee
    British Journal of Cancer, 2024, 130 : 425 - 433
  • [6] Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
    Lindemann, K.
    Kristensen, G.
    Mirza, M. R.
    Davies, L.
    Hilpert, F.
    Romero, I.
    Ayhan, A.
    Burges, A.
    Rubio, M. J.
    Raspagliesi, F.
    Huizing, M.
    Creemers, G. -J.
    Lykka, M.
    Lee, C. K.
    Gebski, V.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1505 - 1510
  • [7] Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
    Bridgewater, JA
    Nelstrop, AE
    Rustin, GJS
    Gore, ME
    McGuire, WP
    Hoskins, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 501 - 508
  • [8] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [9] Treatment Response with Ca-125 in Ovarian Cancer Patients: Comparison among RECIST, WHO, Tridimensional and 3D Volumetric Criteria
    Oliveira, G.
    Zondervan, R.
    Harris, G.
    Hodge, S.
    Harisinghani, M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 192 (05)
  • [10] Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors.
    Campoverde, Leticia
    Da Silva, Laercio Lopes
    Silveira, Hyan
    Nogueira, Wilson Coelho
    Mina, Lida A.
    Lopes, Gilberto
    Batalini, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17615 - E17615
12345